Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no licensed weight loss injection that is completely free of side effects. What clinical trials do show is that side effects from medicines like Mounjaro (tirzepatide) and Wegovy (semaglutide) are usually gastrointestinal, often mild, and tend to settle as the body adjusts — though this varies between individuals. These are prescription-only medicines requiring clinical assessment before any treatment begins. Understanding what side effects to expect, what helps, and when to seek medical attention is the most useful thing you can do before starting.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The phrase you see across the internet ('weight loss injection without side effects') sets an expectation that no licensed medicine can meet. That isn't a reason to be put off. It is a reason to go in with accurate information rather than vague reassurance.
Both Mounjaro and Wegovy work by acting on gut-hormone receptors that regulate appetite and slow gastric emptying. It is exactly this mechanism that produces results, and it is the same mechanism that explains why the digestive system needs time to adapt. Nausea is not an accident; it is the stomach adjusting to food moving through it more slowly. Most people find it manageable, and many find it fades after the first few weeks at a new dose.
The licensed approach in the UK is a gradual dose titration, treatment begins at a lower, tolerability-focused dose and progresses in steps over several months under a prescriber's supervision. The NHS patient information on tirzepatide explains this clearly: the starting dose is not the maintenance dose, and the gap between them gives the body time to settle. Comparing the side effect rate at the starting dose with that at the maximum dose is comparing two different experiences.
If you are wondering about options that avoid injections altogether, non-injection weight loss treatments are worth understanding before you decide.
The NHS semaglutide information page and corresponding guidance for tirzepatide both list a similar cluster of common effects: nausea, vomiting, diarrhoea, constipation, indigestion, burping, fatigue and headache. Injection-site reactions (mild redness or discomfort at the abdomen, thigh or upper arm) are also reported. Rotating the injection site each week reduces this.
Practical things that help with the GI effects are consistent across clinical guidance: eating smaller portions, avoiding very fatty or spicy foods around injection day, keeping hydrated, and not lying down immediately after eating. None of this is complex, but it does make a measurable difference for most people. Our prescribers discuss this in detail as part of aftercare, it is not information you receive once and then have to find again.
The full side effect profile of weight loss injections covers these points in more depth, including what tends to differ between tirzepatide and semaglutide and how frequency data from clinical trials compares to real-world reporting. It is worth reading before you make a treatment decision.
If you are curious about which injection tends to produce fewer or more tolerable side effects for different people, that page covers the published comparison data.
Most side effects from GLP-1 medicines are inconvenient rather than dangerous. A handful are not. Knowing the difference matters more than any general side effect comparison.
Seek urgent medical attention if you experience severe, persistent stomach pain that moves towards your back, with or without vomiting. This pattern can signal acute pancreatitis. In January 2026, the MHRA issued a formal Drug Safety Update reinforcing that acute pancreatitis is a known, infrequent but serious risk associated with GLP-1 receptor agonist medicines, and that patients should stop treatment and seek help immediately if these symptoms occur.
Other situations that need prompt medical review: signs of an allergic reaction (swelling of the face, lips or throat, difficulty breathing), symptoms of severe dehydration from prolonged vomiting or diarrhoea, gallbladder pain, and any new or worsening thoughts about self-harm or mood changes. These are rare, but they are not hypothetical, they appear in the SmPCs because they have been reported.
If something concerns you and you are not sure whether it is urgent, contact a prescriber or call 111 rather than waiting. Patients at nume can reach our clinical team through priority aftercare available seven days a week. If you have a concern that does not feel time-critical, our support team can direct you to the right person.
You can also report any suspected side effect from a licensed medicine at the MHRA Yellow Card scheme, your report contributes to the ongoing safety picture for these medicines.
People often ask whether the side effects are worth it. That is a genuinely personal question, and a prescriber is the right person to help you answer it for your specific health picture, not a comparison article online.
What the evidence does say is that, for the majority of people who complete tirzepatide trials, side effects were manageable enough that they continued. In SURMOUNT-1, involving over 2,500 adults with obesity, most discontinuations related to GI side effects occurred in the earlier titration phase, not at maintenance. That context matters when weighing the decision.
At nume, your consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers, checks your history and decides whether treatment is appropriate. Once approved, your medication arrives the next working day via DPD in plain, unbranded packaging. The pen itself is small, pre-filled and designed to be straightforward to use; the instructions are in the box, and our prescribers are reachable if you have questions after it arrives.
For a broader look at how the different UK-licensed weight loss injections compare, including what you should know about glucose injections for weight loss, or to explore how these injections work in practice, those pages go into more detail. Our clinical team oversees every prescription issued through nume. If you are ready to find out whether treatment is suitable for you, start your free consultation, our prescribers discuss suitability and side effects as part of that process.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.